Value of Ultra-fast Prostate MRI in Prostate Cancer

NCT05903781 | Completed

• 1 other identifier: Ultra- Fast Prostate MRI
• Study Type: observational
• Target: 536
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to assess the value of ultra-fast MRI sequences in the assessment of prostate cancer, compared to the full multiparametric/biparametric protocol as the clinical standard.

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Diagnostic accuracy of ultrafast bpMRI of the prostate

  Diagnostic accuracy of ultrafast bpMRI of the prostate

  1.5 years

Interventions

Prostate MRI DIAGNOSTIC_TEST

MRI of the prostate

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

ca. 300 men with suspected prostate cancer

You may qualify if:

• Patients who undergo clinically indicated MR imaging of the prostate
• Informed consent as documented by signature (Informed Consent Form)
• Patients ≥18 years of age

You may not qualify if:

• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
• Previous enrolment into the current study
• Enrolment of the investigator, his/her family members, employees and other dependent persons
• Patients with non-MRI compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-MRI compatible implants).
• Patients with known hypersensitivity reactions to MRI contrast agents will undergo the examination without application of a contrast agent

Sponsors & Collaborators

• University of Zurich: lead

Study Sites (1)

University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2023
• First Posted: June 15, 2023
• Study Start: June 26, 2023
• Primary Completion: February 18, 2025
• Study Completion: February 18, 2025
• Last Updated: May 14, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)